Established in 1997, Chengdu Rong Sheng Pharmaceutical Co., Ltd. is the core subsidiary of Tiantan Biological Products Co., Ltd., a state-owned listed enterprise. Its address is located at No.7 Keyuan South Road, Qipaoyuan, Chengdu High-tech Zone. Its legal representative is Yu Ding, who belongs to China National Pharmaceutical Group Co., Ltd., a fortune 500 company, and is mainly engaged in the production, scientific research and sales of blood products. Is a high-tech biopharmaceutical enterprise. In the early 1980s, the first batch of apheresis plasma stations were built in China, which has rich experience in raw plasma management. Since 1980, it has taken the lead in realizing the industrial production of blood products in China and created many firsts in this industry in China.
The Development Course of Chengdu Rong Sheng
1 and 1980 took the lead in starting the industrial production of blood products in China, engaged in the research and development and industrial production of blood products, obtained the marketing license for intramuscular injection of human immunoglobulin, and went on sale.
2.65438-0988, the first human-derived tetanus immunoglobulin was listed in China, and the intramuscular injection production license of tetanus immunoglobulin was obtained in the institute.
3. 1992, the first immunoglobulin for intravenous injection was listed in China.
4. 1997 Chengdu Rong Sheng was established, which took the lead in introducing the production technology of filter press in China and promoted the technical upgrading of the industry.
During the period of 5. 1998, the first batch passed the GMP certification of the US Food and Drug Administration in China.
6.200 1, Chengdu Institute of Biological Products injected the assets of blood products business into Rong Sheng, Chengdu.
7. In 2006, the new factory building of Keyuan South Road was put into use.
8. In 2007, Dujiangyan, Nanjiang, Renshou and Gaoxian 10 pulp stations in Sichuan were converted and acquired.
9. In 2009, it was merged into China Pharmaceutical Group, the largest medical and health industry group in China.
In 10 and 20 10, it passed the ISO900 1, ISO 1400 1, OHSAS 1800 1 certification.
In 1 1 year and 20 12 years, human hepatitis B immune protein spheres for intravenous injection were successfully developed.
12 and 20 17 acquired 80% equity of Sinopharm Guizhou Blood Products Co., Ltd., and Sinopharm Zhongsheng invested its blood products business-related assets in Chengdu Rong Sheng. Sinopharm Shanghai Blood Products Co., Ltd., Sinopharm Wuhan Blood Products Co., Ltd. and Lanzhou Lansheng Blood Products Co., Ltd. became wholly-owned subsidiaries of Chengdu Rong Sheng.
13 and 20 18 acquired 20% equity of Guizhou blood products co., ltd of sinopharm group, and took the lead in obtaining clinical approval for recombinant human coagulation factor 8 in China.
abstract
Chengdu Rong Sheng takes love and responsibility as its core values, upholds the concept of caring for life and health, takes the mission of promoting the development of blood industry and serving healthy China, and is committed to becoming a leading and internationally renowned blood products enterprise in China.